Akorn Pharmaceuticals Inc. Decatur, IL. 483 Issued 06/10/2016
Similar Posts
FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease
FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial diseaseCDER SBIA Chronicles
FDA/CDER SBIA Chronicles, the bi-monthly newsletter of the CDER Small Business and Industry Assistance team, provides industry with useful information to assist in all aspects of drug marketing and regulationOtsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 20 mEq Potassium Chloride Injection Due To Overwrap Mislabeled As 10 mEq Potassium Chloride Injection
FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the productNat’s Nuts Issues Allergy Alert on Potential Undeclared Cashews in Nat’s Nuts Brand Cinnamon Whiskey Pecans
Nat’s Nuts of Rochester, NY is recalling 600 bags of Cinnamon Whiskey Pecans, because they may contain undeclared cashews. People who have an allergy or severe sensitivity to cashews run the risk of serious or life-threatening allergic reaction if they consume these products.Thea Pharma, Inc. – 712416 – 07/09/2025
Unapproved New Drugs/MisbrandedRecall Alert: Max Mobility/Permobil Removes All SpeedControl Dials Used with SmartDrive MX2+ Power Assist Devices
SpeedControl Dials used with SmartDrive MX2+ Power Assist Devices may be unresponsive to users and fail to stop or start unexpectedly, causing injury